RPN10 Antibody

What is the biological function of RPN10/Rpn10?

RPN10/Rpn10 functions as a subunit of the 19S proteasome regulatory complex that recognizes and binds polyubiquitinated proteins, facilitating their degradation by the 26S proteasome. It contains ubiquitin interacting motifs (UIMs) that specifically recognize ubiquitinated substrates. The protein plays a critical role in the ubiquitin-proteasome pathway by helping to feed target proteins into the catalytic machinery of the proteasome. Research has established that Rpn10 is involved in both standard proteasome and immunoproteasome activity, making it a particularly attractive research target in the context of cancer biology and immunology .

What post-translational modifications affect RPN10 function?

The primary post-translational modification affecting RPN10 function is monoubiquitination. This modification has profound effects on proteasome function by regulating Rpn10's capacity to interact with substrates through inhibition of its ubiquitin interacting motif (UIM). The Rsp5 ubiquitin ligase (ortholog of mammalian NEDD4.2) and the Ubp2 deubiquitinating enzyme control the levels of Rpn10 monoubiquitination in vivo. Importantly, monoubiquitinated Rpn10 (mUb-Rpn10) has been detected both in proteasome-associated fractions and in non-proteasomal fractions, indicating multiple functional states. This monoubiquitination state appears to be responsive to cellular stress, providing a regulatory mechanism for proteasome function .

What are the recommended methods for studying RPN10 protein-protein interactions?

For studying RPN10 protein-protein interactions, several complementary approaches have proven effective:

• AlphaScreen Assays: These provide a high-throughput screening method for identifying compounds that interfere with RPN10-ubiquitin interactions. The assay typically uses GST-tagged Rpn10 and biotinylated ubiquitin chains (Ub₂₋₇) to detect binding in 384-well plate formats. This technique has been successfully used to screen libraries of thousands of compounds, with results measured as percent inhibition relative to no-compound controls .

• Field Effect Biosensor (FEB) Assays: This method involves immobilizing recombinant His-tagged Rpn10 on a graphene chip surface to monitor real-time changes in electrical current and capacitance when exposed to ligands. The approach allows for accurate determination of dissociation constants (Kd) and provides insights into binding kinetics .

• Microscale Thermophoresis (MST): This technique measures the binding affinity between GFP-fusion Rpn10 protein and potential ligands. The method typically uses a buffer containing Tris-HCl, NaCl, and dithiothreitol, with samples analyzed using systems like MONOLITH NT.115 .

These methods can be used individually or in combination to validate findings and provide comprehensive characterization of RPN10 interactions.

How should I design knockout or knockdown experiments for RPN10?

When designing RPN10 knockout or knockdown experiments, consider these methodological approaches:

• CRISPR/Cas9 Inducible Knockout System:

  • Use lentivirus expressing inducible Cas9 (selection with G418)

  • Follow with lentivirus expressing sgRNA targeting Rpn10 (selection with puromycin)

  • Induce Cas9 protein expression using doxycycline (0.5 μg/mL every other day)

  • Verify knockout efficiency by western blot

• shRNA Knockdown Approach:

  • Employ multiple different shRNAs (at least 3) to ensure specificity

  • Include rescue experiments by re-expressing Rpn10 to confirm that observed effects are not due to off-target activity

  • Consider inducible systems where doxycycline withdrawal allows re-expression to confirm phenotype reversibility

• Experimental Controls:

  • Include parallel knockdowns of related proteins (e.g., Rpn13) for comparative analysis

  • Assess effects on both standard proteasome and immunoproteasome activity

  • Measure accumulation of ubiquitinated proteins as a functional readout of proteasome disruption

The experimental design should include both in vitro cell viability/proliferation assays and in vivo models for comprehensive characterization of phenotypic effects.

What techniques are effective for monitoring RPN10 monoubiquitination?

Monitoring RPN10 monoubiquitination requires specialized techniques:

• Western Blot Analysis: Use anti-Rpn10 antibodies to detect both unmodified and monoubiquitinated forms, which appear as bands with slower mobility due to the addition of ubiquitin (~8-10 kDa increase). Multiple monoubiquitination events may produce additional higher molecular weight bands .

• Tandem Affinity Purification: Express Rpn10 with a C-terminal TAP tag to enable purification of the protein and its modified forms from cell lysates. This approach allows for isolation of relatively pure Rpn10 protein populations for subsequent analysis .

• Size Exclusion Chromatography: Fractionate cell extracts using Superose 6 chromatography to separate proteasome-associated and free forms of Rpn10. Follow with immunodetection of specific fractions to assess the distribution of monoubiquitinated forms .

• In Vitro Ubiquitination Assays: Reconstitute the ubiquitination reaction using purified components (E1, E2, Rsp5/NEDD4 as E3, ubiquitin, and recombinant Rpn10) to study the process under controlled conditions .

The level of monoubiquitination can be influenced by cell culture conditions and stress factors, so experimental controls should include appropriate physiological contexts.

How can RPN10 antibodies be used in proteomic analyses of the ubiquitin-proteasome system?

RPN10 antibodies serve as valuable tools in advanced proteomic analyses of the ubiquitin-proteasome system:

• Tandem Mass Tag (TMT)-Based Proteomic Analysis:

  • Use RPN10 antibodies for immunoprecipitation followed by TMT labeling

  • Analyze samples by LC-MS3 to identify proteins whose abundance changes upon Rpn10 knockout or inhibition

  • Filter peptide spectral matches to a 1% false discovery rate using target-decoy strategy

  • Adjust p-values for protein differentiation analysis using the Benjamini-Hochberg method

• Pathway Analysis of Proteomic Data: Studies utilizing this approach have revealed that inhibiting Rpn10 affects multiple cellular pathways including:

  • Increased autophagy

  • Enhanced antigen presentation

  • Activation of CD4 T and natural killer cells

  • Accumulation of polyubiquitinated proteins

  • Cell cycle arrest

  • Activation of caspases and unfolded protein response pathways

This comprehensive profiling enables researchers to understand the wider impact of Rpn10 inhibition beyond direct effects on the proteasome.

What are the key considerations when evaluating RPN10 inhibitors in therapeutic contexts?

When evaluating RPN10 inhibitors for potential therapeutic applications, researchers should consider:

• Selectivity Assessment:

  • Compare effects on target cells versus normal cells (e.g., MM cells vs. normal peripheral blood mononuclear cells)

  • Determine whether the inhibitor blocks 20S proteasome catalytic function or 19S deubiquitinating activity

  • Evaluate effects in the presence of tumor-promoting microenvironments (e.g., bone marrow milieu for MM)

• Resistance Evaluation:

  • Test inhibitors on both proteasome inhibitor-sensitive and -resistant cell lines

  • Assess mechanisms of resistance and whether RPN10 inhibition can overcome them

  • Combine with other therapeutic agents to evaluate potential synergies

• In Vivo Efficacy and Safety:

  • Examine tumor growth inhibition in xenograft models

  • Monitor survival rates

  • Assess tolerability and toxicity profiles

  • Compare efficacy to established therapeutic agents

The drug SB699551 (SB) has been identified as a novel RPN10 inhibitor through AlphaScreen high-throughput screening and has shown promise in decreasing viability of MM cell lines, leukemic cell lines, and primary cells from MM patients without affecting normal peripheral blood mononuclear cells .

How should conflicting data on RPN10 function be reconciled in research?

When faced with conflicting data about RPN10 function, consider these analytical approaches:

• Contextual Analysis:

  • Cell type-specific functions: RPN10's role may differ between cell types (e.g., more critical in MM cells than in normal plasma cells)

  • Species-specific differences: Yeast Rpn10 and human PSMD4 may have evolved distinct regulatory mechanisms

  • Experimental conditions: Stress conditions alter RPN10 monoubiquitination, potentially changing its function

• Mechanistic Investigations:

  • Dissect involvement in standard proteasome versus immunoproteasome: Evidence suggests Rpn10, but not Rpn13, has a role in immunoproteasome function

  • Distinguish between proteasomal and non-proteasomal functions: Monoubiquitinated Rpn10 exists in both proteasome-associated and free forms

  • Examine compensatory mechanisms: Other ubiquitin receptors may compensate for Rpn10 loss in certain contexts

• Technical Reconciliation:

  • Compare antibody specificities and epitopes when different antibodies yield contradictory results

  • Evaluate knockout/knockdown efficiencies and potential off-target effects

  • Consider temporal dynamics of protein depletion and cellular adaptation

A systematic approach to reconciling conflicting data can lead to deeper insights into RPN10's complex roles in cellular physiology.

What are common pitfalls in RPN10 antibody-based experiments and how can they be avoided?

Researchers working with RPN10 antibodies should be aware of these common challenges:

• Cross-Reactivity Issues:

  • RPN10 has alternative names (including SUN1, MCB1) and this can cause confusion as SUN1 is also the name of an unrelated nuclear envelope protein

  • Verify antibody specificity using appropriate knockout controls

  • Use multiple antibodies targeting different epitopes to confirm findings

• Detection of Modified Forms:

  • Standard western blot conditions may not efficiently resolve monoubiquitinated from unmodified RPN10

  • Use gradient gels (e.g., 4-12%) for better separation of modified forms

  • Consider using ubiquitin-specific antibodies in conjunction with RPN10 antibodies for co-detection

• Antibody Selection for Different Applications:

  • Some antibodies may work well for western blotting but poorly for immunoprecipitation or immunofluorescence

  • Validate each antibody for the specific application intended

  • Consider species reactivity when working with model organisms (antibodies may be specific to yeast, human, or other species)

Careful validation and control experiments are essential for generating reliable data with RPN10 antibodies.

How can researchers optimize immunoprecipitation protocols for RPN10?

For successful RPN10 immunoprecipitation experiments, consider these optimization strategies:

• Lysis Buffer Composition:

  • Use buffers containing protease inhibitors to prevent degradation

  • Include deubiquitinase inhibitors (e.g., N-ethylmaleimide) when studying ubiquitinated forms

  • For proteasome-associated RPN10, include ATP in buffers to maintain complex integrity

  • Consider detergent types and concentrations based on experimental goals

• Antibody Selection and Application:

  • Test multiple antibodies targeting different epitopes

  • Consider using tagged versions (e.g., TAP-tagged Rpn10) for efficient pull-down

  • For co-immunoprecipitation of interacting partners, gentler wash conditions may be required

  • Crosslinking approaches may help capture transient interactions

• Controls and Validation:

  • Include RPN10 knockout/knockdown samples as negative controls

  • Use recombinant RPN10 protein as a positive control

  • Verify successful immunoprecipitation by western blotting before proceeding to downstream applications

  • Consider competitive elution with epitope peptides for cleaner preparations

Optimized immunoprecipitation protocols are essential for studying RPN10's interactions and post-translational modifications.

What emerging technologies might advance our understanding of RPN10 function?

Several cutting-edge technologies hold promise for deepening our understanding of RPN10:

• Cryo-EM Structural Analysis:

  • High-resolution structural studies of RPN10 within the intact proteasome complex

  • Visualization of conformational changes upon monoubiquitination

  • Structural basis for interactions with inhibitors like SB699551

• Proximity Labeling Approaches:

  • BioID or APEX2 fusions to map the RPN10 interactome in living cells

  • Temporal analysis of interaction dynamics during cell cycle or stress responses

  • Comparison of interactomes between monoubiquitinated and unmodified RPN10

• Single-Cell Proteomics:

  • Analysis of RPN10 expression and modification states at single-cell resolution

  • Correlation with cell cycle phase, differentiation state, or disease progression

  • Integration with transcriptomic data for systems-level understanding

These emerging approaches may reveal previously unrecognized aspects of RPN10 biology and open new therapeutic avenues.

How might RPN10-targeted therapies evolve based on current research?

Current research suggests several promising directions for RPN10-targeted therapeutic development:

• Selective Inhibitor Optimization:

  • Structure-based drug design using the hit compound SB699551 as a starting point

  • Development of inhibitors that specifically disrupt interactions with ubiquitinated substrates without affecting proteasome assembly

  • Investigation of tissue-specific delivery strategies to enhance therapeutic index

• Combination Therapy Approaches:

  • Rational combinations with existing proteasome inhibitors like bortezomib

  • Integration with immunotherapies based on findings that Rpn10 inhibition increases antigen presentation and immune cell activation

  • Development of sequential treatment protocols to overcome resistance mechanisms

• Biomarker Development:

  • Utilization of RPN10 expression levels as predictive biomarkers for therapy response

  • Monitoring of monoubiquitination status as an indicator of cellular stress and proteasome function

  • Integration of multiple ubiquitin-proteasome system markers for personalized treatment approaches

The evolution of RPN10-targeted therapies represents a promising frontier in the treatment of multiple myeloma and potentially other cancers.